Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-25 @ 2:09 AM
NCT ID:
NCT06666660
Eligibility Criteria:
Inclusion Criteria
Participants will be recruited if they fall in the following categories:
1. Relatively healthy middle aged (40-60 years) man or woman;
2. Completed the pre-screening requirements and has managed to schedule the screening visit;
3. Met the randomization criteria after the screening visit i.e., your biological age (as measured by blood DNA methylation) is greater than the chronological age;
4. Able to attend all 4 research visits for screening and research data collection at the NUHS Centre for Healthy Longevity (CHL) at Alexandra Hospital or MD11, National University of Singapore.
5. Willing to wear an OURA ring for 14 consecutive days after each study visits.
6. Willing to download study platform application into their mobile phone throughout the study period.
Exclusion Criteria
Participants will NOT be recruited if they fall in any one or more of the following categories:
1. BMI lower than 18 kg/m2 or higher than or equal to 30 kg/m2 \[25\];
2. Pre-existing, or history of major cardiovascular diseases (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (more than 1 prescribed medication), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism;
3. Type 1 diabetes and Type 2 diabetes;
4. Active cancer or treatment of cancer in the last 3 years;
5. Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications);
6. Pregnant women or women planning pregnancy in the next 12 months;
7. Multiple sclerosis or autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease;
8. Recent history of sepsis or infection (within 3 months of in-patient hospitalisation);
9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders;
10. Hepatitis and liver cirrhosis (independent of severity);
11. Severe kidney disease (GFR less than 30 ml/min/1.73 m2);
12. Skin disease (on systemic medication);
13. Individuals who are on another trial that requires them taking similar or partially similar investigational product (Appendix 1);
14. Individuals who are advised by their medical practitioner to take a MVM supplement;
15. Refuse to stop taking any non-prescribed supplements that contain the investigational product (Appendix 1) within one month before the screening visit and during the study period;
16. Taking a medically prescribed supplements that contains 2 or more of the ingredients of the investigational product (Appendix 1);
17. Individuals with planned hospitalization in the next 12 months;
18. Any serious medical illness which in the PI's judgment may jeopardise the participant by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
40 Years
Maximum Age:
60 Years
Study:
NCT06666660
Study Brief:
Protocol Section:
NCT06666660